| Dr Bradford Deahl Granath, MD | |
|
3915 Talbot Rd S Ste 401, Renton, WA 98055-5738 | |
| (425) 690-3445 | |
| (425) 690-9445 |
| Full Name | Dr Bradford Deahl Granath |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 39 Years |
| Location | 3915 Talbot Rd S Ste 401, Renton, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164521670 | NPI | - | NPPES |
| 29D1045101 | Other | NV | CLIA WAIVED # |
| 100507165 | Medicaid | NV | |
| 11269 | Other | NV | STATE LICENCE # |
| 100507319 | Medicaid | NV | |
| 203580193 | Other | NV | TAX ID |
| CC1838 | Other | NV | BLUECROSS BLUESHIELD # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11269 (Nevada) | Secondary |
| 207Q00000X | Family Medicine | MD00025394 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Valley Medical Center | Renton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Medical Group-renton | 4183753965 | 408 |
| Overlake Medical Clinics Llc | 7012808827 | 350 |
News Archive
Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.
A California nonprofit meant to facilitate health information exchange has closed its doors after losing a bid to become the state's main exchange organization, Modern Healthcare reports. Board members for California Regional Health Information Organization, or CalRHIO, voted to disband after their company failed to win contracts with the state or negotiate a partnership that would fulfill state requirements.
The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
› Verified 2 days ago
| Entity Name | Overlake Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.
A California nonprofit meant to facilitate health information exchange has closed its doors after losing a bid to become the state's main exchange organization, Modern Healthcare reports. Board members for California Regional Health Information Organization, or CalRHIO, voted to disband after their company failed to win contracts with the state or negotiate a partnership that would fulfill state requirements.
The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
› Verified 2 days ago
| Entity Name | Valley Medical Group-renton |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619209574 PECOS PAC ID: 4183753965 Enrollment ID: O20100604000113 |
News Archive
Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.
A California nonprofit meant to facilitate health information exchange has closed its doors after losing a bid to become the state's main exchange organization, Modern Healthcare reports. Board members for California Regional Health Information Organization, or CalRHIO, voted to disband after their company failed to win contracts with the state or negotiate a partnership that would fulfill state requirements.
The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradford Deahl Granath, MD 3600 Lind Ave Sw, Suite 100 Attn Credentialing, Renton, WA 98057 Ph: (425) 690-3445 | Dr Bradford Deahl Granath, MD 3915 Talbot Rd S Ste 401, Renton, WA 98055-5738 Ph: (425) 690-3445 |
News Archive
Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.
A California nonprofit meant to facilitate health information exchange has closed its doors after losing a bid to become the state's main exchange organization, Modern Healthcare reports. Board members for California Regional Health Information Organization, or CalRHIO, voted to disband after their company failed to win contracts with the state or negotiate a partnership that would fulfill state requirements.
The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.
› Verified 2 days ago
Dominique James Nguyen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3915 Talbot Rd S Ste 200, Renton, WA 98055 Phone: 425-690-3400 Fax: 425-690-0600 | |
Dr. Tory John Olsen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 S 43rd St, Renton, WA 98055 Phone: 425-656-4224 | |
Anna Eleanor Goebel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Ne 4th St Ste 105, Renton, WA 98056 Phone: 425-690-3410 Fax: 425-690-9410 | |
Sumam Marion Abraham, Family Medicine Medicare: Medicare Enrolled Practice Location: 275 Bronson Way Ne, Renton, WA 98056 Phone: 425-235-2800 | |
John L. Bondi, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3915 Talbot Rd S, Ste 401, Renton, WA 98055 Phone: 425-656-4224 | |
Arkadiy B. Tkachev, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 S Carr Rd, Suite 100, Renton, WA 98055 Phone: 415-227-3700 | |
Daniel L Brelsford, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Ne 4th St, Ste 105, Renton, WA 98056 Phone: 425-690-3410 Fax: 425-690-9410 |